Purged Autologous Bone Marrow: Better or Worse than Circulating Stem Cells?

  • J. Reiffers
Part of the Developments in Hematology and Immunology book series (DIHI, volume 25)

Abstract

Autologous bone marrow tranplantation (ABMT) has been extensively used as treatment for hematological malignancies over the last decade [1]. The main cause of failure after ABMT is relapse or recurrence of the underlying disease which at least in some cases could be due to the reinfusion of malignant cells present in the marrow inoculum. Thus,different methods of purging, using immunological, physical or chemical techniques were proposed for “ex vivo” treatment of bone marrow cells. Recently peripheral blood stem cells (PBSC) were demonstrated to be able to reconstitute complete and stable hematopoiesis following supralethal therapy [2]. It has been hypothesized that PBSC may be less contaminated by residual tumor cells than bone marrow cells.Thus, autologous blood stem cell transplantation (ABSCT) could be used instead of (purged or unpurged) ABMT.

Keywords

Toxicity Lymphoma Leukemia Oncol Melphalan 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Goldstone AH, Gribben JG. The role of autologous bone marrow transplantation in the treatment of malignant disease. Blood Reviews 1987; 1:193– 200.PubMedCrossRefGoogle Scholar
  2. 2.
    Reiffers J, Leverger G, Marit G, et al. Hematopoietic reconstitution after autologous blood stem cell transplantation. In: Gale RP, Champlin RE (eds). Bone marrow transplantation: Current controversies. New York: Alan R Liss, Inc 1989:313–20.Google Scholar
  3. 3.
    Kessinger A, Armitage JO, Smith DM, Landmark JD, Bierman PJ, Weissenburger DD. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989;74: 1260–5.PubMedGoogle Scholar
  4. 4.
    To LB, Haylock DN, Kimber RJ, Juttner CA. High levels of circulating hemopoietic stem cells in very early remission from acute non-lympho-blastic leukemia and their collection and cryopreservation. Br J Haematol 1984;58:399–410.PubMedCrossRefGoogle Scholar
  5. 5.
    Haas R, Ho AD, Bredthauer U, Cayeux S, Egerer G, Knauf W, Hunstein W. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1990;18:94–8.PubMedGoogle Scholar
  6. 6.
    Reiffers J, Vezon G, Bernard Ph, et al. Stem cell apheresis in patients with acute nonlymphocytic leukemia. Plasma Ther Transfus Technol 1988;9: 115–8.CrossRefGoogle Scholar
  7. 7.
    To LB, Dyson PG, Juttner CA. Cell-dose effect in circulating stem cell autografting. Lancet 1986;ii:404–5.CrossRefGoogle Scholar
  8. 8.
    Juttner CA, To LB, Haylock DN, Branford A, Kimber RJ. Circulating autologous stem cells collected in very early remission from acute non-lympho- blastic leukemia produce prompt but incomplete hemopoietic reconstitution after high dose Melphalan or supralethal chemoradiotherapy. Br J Haematol 1985;61:739–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Jones RJ, Celano P, Sharkis SJ, Sensenbrenner LL. Two phases of engraftment established by serial bone marrow transplantation in mice. Blood 1989;73:397–401.PubMedGoogle Scholar
  10. 10.
    Burnett AK, Tansey P, Watkins R, et al. Transplantation of unpurged autologous bone marrow in acute myeloid leukemia in first remission. Lancet 1984;i:1068–70.CrossRefGoogle Scholar
  11. 11.
    Dicke KA, Zander A, Spitzer G, et al. Autologous bone marrow transplantation in relapsed adult acute leukemia. Lancet 1989;i:514–7.Google Scholar
  12. 12.
    Harada M, Yoshida T, Ishino C, et al. Hematologic recovery following autologous and allogeneic bone marrow transplantation. Exp Hematol 1983;11:841–8.PubMedGoogle Scholar
  13. 13.
    Douay L, Gorin NC, Mary JY, et al. Recovery of CFU-GM from cryopre-served marrow and in vivo evaluation after autologous bone marrow trans- plantation are predictive of engraftment. Exp Hematol 1986;14:358–65.PubMedGoogle Scholar
  14. 14.
    Gorin NC, Douay L, Laporte JP, et al. Autologous bone marrow transplantation using marrow incubated with Asta Z 7557 in adult acute leukemia. Blood 1986;67:1367–76.PubMedGoogle Scholar
  15. 15.
    Rowley SD, Zuehlsdorf M, Braine HG, et al. CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Blood 1987;70:271–5.PubMedGoogle Scholar
  16. 16.
    Ball ED, Mills LE, Coughlin CT, Beck JR, Cornwell GG. Autologous bone marrow transplantation in acute myelogenous leukemia: In vitro treatment with myeloid cell-specific monoclonal antibodies. Blood 1986; 68:1311–5.PubMedGoogle Scholar
  17. 17.
    Gianni AM, Bregni M, Siena S, et al. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy? Hemat Oncol 1989;7:139–48.Google Scholar
  18. 18.
    Lopez M, Pouillart, Mortel O, et al. Infusion of autologous peripheral blood nucleated cells hastens hematological recovery after high dose chemotherapy and autologous transplantation of bone marrow purged in vitro with Mafosfamide. Exp Hematol 1989;17:651 (abstr 361).Google Scholar
  19. 19.
    Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic recon- stitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988;318:869–76.PubMedCrossRefGoogle Scholar
  20. 20.
    Sheridan WP, Morstyn G, Wolf M, et al. Granulocytic colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;ii:891–5.CrossRefGoogle Scholar
  21. 21.
    Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D.-Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074–81.PubMedGoogle Scholar
  22. 22.
    Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating hemopoietic progenitor cell compartment in man. Lancet 1988;i:1194–8.CrossRefGoogle Scholar
  23. 23.
    Kurtzberg WP, Kirkpatrick G, Arwater S, et al. GM-CSF primed peripheral blood progenitor cells (PBSC) coupled with autologous bone marrow transplantation (ABMT) will eliminate absolute leukopenia following high dose chemotherapy (HDC). Blood 1989;74(suppl 1):50a(abstr 178).Google Scholar
  24. 24.
    Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating hemopoietic stem cells for auto- transplantation. Lancet 1989;ii:580–5.CrossRefGoogle Scholar
  25. 25.
    Ventura GJ, Spitzer G, Hester JP, Gutterman RO, Deisseroth AB. A controlled trial of mobilized peripheral blood progenitor cells (PBSC), does their addition to autologous bone marrow transplant and growth factor (ABMT + GF) cause faster hematopoietic recovery? J Clin Oncol 1990; 9:9(abstr 28).Google Scholar
  26. 26.
    Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A european survey of the role of marrow purging. Blood 1990;75:1606–14.PubMedGoogle Scholar
  27. 27.
    Cahn JY, Hervé P, Flesch M, et al. Autologous bone marrow transplantation (ABMT) for acute leukemia in complete remission: A pilot study of 33 cases. Br J Haematol 1986;63:457–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Löwenberg B, Verdonck LJ, Dekker W, et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: Results of a dutch prospective study. J Clin Oncol 1990;8:287–94.PubMedGoogle Scholar
  29. 29.
    Fermand JP, Levy Y, Gerota J, et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989;73:20–3.PubMedGoogle Scholar
  30. 30.
    Ventura GJ, Barlogie B, Hester JP, et al. High dose cyclophosphamide, BCNU and VP 16 with autologous blood stem cell support for refractory multiple myeloma. BMT 1990;5:265–8.Google Scholar
  31. 31.
    Marit G, Boiron JM, Reiffers J. Autologous blood stem cell transplantation in high risk myeloma. BMT 1990;5(suppl 1):55.Google Scholar
  32. 32.
    Körbling M, Haas R, Knauf W, Holle R, Hunstein W. Therapeutic efficacy of autologous blood stem cell transplantation (ABSCT): The role of cyto-toxic/cytokine stem cell mobilization. BMT 1990;5(suppl.1):39–40.Google Scholar
  33. 33.
    Juttner CA, To LB, Haylock DN, et al. Approaches to blood stem cell mobilization. Initial australian clinical results. BMT 1990;5(suppl.1):22-3.Google Scholar
  34. 34.
    Reiffers J, Marit G, Boiron JM, et al. Autologous stem cells transplantation in acute leukemia: Present status and future directions. BMT 1990;5 (suppl.1):48–9.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1991

Authors and Affiliations

  • J. Reiffers

There are no affiliations available

Personalised recommendations